CD39+ conventional CD4+ T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade

Oncoimmunology. 2023 Aug 18;12(1):2246319. doi: 10.1080/2162402X.2023.2246319. eCollection 2023.

Abstract

Conventional CD4+ T (Tconv) lymphocytes play important roles in tumor immunity; however, their contribution to tumor elimination remains poorly understood. Here, we describe a subset of tumor-infiltrating Tconv cells characterized by the expression of CD39. In several mouse cancer models, we observed that CD39+ Tconv cells accumulated in tumors but were absent in lymphoid organs. Compared to tumor CD39- counterparts, CD39+ Tconv cells exhibited a cytotoxic and exhausted signature at the transcriptomic level, confirmed by high protein expression of inhibitory receptors and transcription factors related to the exhaustion. Additionally, CD39+ Tconv cells showed increased production of IFNγ, granzyme B, perforin and CD107a expression, but reduced production of TNF. Around 55% of OVA-specific Tconv from B16-OVA tumor-bearing mice, expressed CD39. In vivo CTLA-4 blockade induced the expansion of tumor CD39+ Tconv cells, which maintained their cytotoxic and exhausted features. In breast cancer patients, CD39+ Tconv cells were found in tumors and in metastatic lymph nodes but were less frequent in adjacent non-tumoral mammary tissue and not detected in non-metastatic lymph nodes and blood. Human tumor CD39+ Tconv cells constituted a heterogeneous cell population with features of exhaustion, high expression of inhibitory receptors and CD107a. We found that high CD4 and ENTPD1 (CD39) gene expression in human tumor tissues correlated with a higher overall survival rate in breast cancer patients. Our results identify CD39 as a biomarker of Tconv cells, with characteristics of both exhaustion and cytotoxic potential, and indicate CD39+ Tconv cells as players within the immune response against tumors.

Keywords: CD39; Cancer; conventional CD4+ T cells; cytotoxicity; exhaustion.

MeSH terms

  • Animals
  • Antineoplastic Agents*
  • Breast Neoplasms* / metabolism
  • CD4-Positive T-Lymphocytes
  • CTLA-4 Antigen
  • Female
  • Humans
  • Mice
  • T-Lymphocytes, Regulatory / metabolism

Substances

  • CTLA-4 Antigen
  • Antineoplastic Agents

Grants and funding

The work was supported by the SiRIC-Curie Program [grant INCa-DGOS-12554]; LabEx DCBIOL [ANR-10-IDEX-0001-02 PSL and ANR-11-LABX-0043]; the Center of Clinical Investigation [CIC IGR-Curie 1428]; Institut National du Cancer 12554 [INCa- DGOSInserm_10.13039/501100006364]; PICT [2018-1787]; SECYT [2018-2022]; PIP-CONICET [2021-2023].